CYP19A1 and breast carcinoma: We next examined the association of these genes with on-treatment Ki67 levels in three clinical studies of ER+ breast cancers treated with a neoadjuvant aromatase inhibitor (Supplementary Table 1; cohort of Guerrero-Zotano17; cohort of Giltnane14; cohort of Miller22).